Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q2 FY24 results · Jul–Sep 2023
Aarti Pharmalabs reported revenue from operations of ₹439.80 crore and net profit of ₹51.80 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 439.80 | — | — | 458.36 | −4.0% |
| Other income | 0.98 | — | — | 0.48 | +104.2% |
| Total income | 440.78 | — | — | 458.84 | −3.9% |
| Profit before tax | 66.95 | — | — | 63.98 | +4.6% |
| Net profit for the period | 51.80 | — | — | 47.09 | +10.0% |
| EPS, basic (₹) | 5.72 | — | — | 5.20 | +10.0% |
| Net margin (%) | 11.8 | — | 10.3 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 356.14 | — | — | 358.14 | −0.6% |
| Other income | 0.00 | — | — | 4.86 | −100.0% |
| Total income | 356.14 | — | — | 363.00 | −1.9% |
| Profit before tax | 53.66 | — | — | 62.13 | −13.6% |
| Net profit for the period | 41.18 | — | — | 47.63 | −13.5% |
| EPS, basic (₹) | 4.61 | — | — | 5.26 | −12.4% |
| Net margin (%) | 11.6 | — | 13.3 |
Consolidated
- Filed with BSE
- 21 Nov 2023, 15:30 IST
- Board meeting
- 07 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Nov 2023, 15:30 IST
- Board meeting
- 07 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Audited
- Source
- XBRL filing on BSE